Anticoagulants in Children with Renal Impairment: A Narrative Review
Seminars in Thrombosis and Hemostasis · 01.10.2025 · 51 (07) · 776-787
DOI: 10.1055/a-2546-0126 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.10.2025. Verfasst von Amy L Kiskaddon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Anticoagulants, Venous Thromboembolism, Renal Insufficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Venous thromboembolism is a common cause of morbidity and mortality in children with renal disease. To properly treat and prevent thromboembolism in this patient population, it is important to be familiar with the multitude of anticoagulant agents currently available. Many anticoagulant drugs undergo some extent of renal elimination. There are important considerations for the selection, dosing, and monitoring of anticoagulant drugs for patients with renal impairment due to various pharmacokinetic alterations that may occur. While there are data to help guide dosing and monitoring in adults, evidence regarding renal dose adjustment of many anticoagulant drugs in children are limited. For the clinician, anticoagulation management in children with renal impairment presents unique challenges. In addition to considering overall bleeding risk, the extent of renal impairment may vary by patient, making a one-size-fits-all approach to managing these patients difficult. These factors, combined with limited data, can make managing anticoagulation in children with renal impairment a challenge. Therefore, the focus of this review will be to describe the pharmacokinetics of the following anticoagulants in children with impaired renal function: unfractionated heparin, enoxaparin, dalteparin, rivaroxaban, apixaban, edoxaban, fondaparinux, bivalirudin, argatroban, dabigatran, and warfarin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Institute for Clinical and Translational Research, Johns Hopkins All Children's, St. Petersburg, Florida.
- Department of Pharmacy, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
- Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
- Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.
Zitieren
APA
Kiskaddon, A. L., Witt, D. M., Betensky, M., Sochet, A. A., Memken, A., Male, C., & Goldenberg, N. A. (2025). Anticoagulants in Children with Renal Impairment: A Narrative Review. Seminars in Thrombosis and Hemostasis, 51(07), 776-787. https://doi.org/10.1055/a-2546-0126
Vancouver
Kiskaddon AL, Witt DM, Betensky M, Sochet AA, Memken A, Male C, et al. Anticoagulants in Children with Renal Impairment: A Narrative Review. Seminars in Thrombosis and Hemostasis. 2025;51(07):776-787. doi:10.1055/a-2546-0126
BibTeX
@article{Kiskaddon2025,
author = {Kiskaddon, Amy L and Witt, Daniel M and Betensky, Marisol and Sochet, Anthony A and Memken, Amanda and Male, Christoph and Goldenberg, Neil A},
title = {Anticoagulants in Children with Renal Impairment: A Narrative Review},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2025},
volume = {51},
number = {07},
pages = {776--787},
doi = {10.1055/a-2546-0126}
}
EUVIMED